<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124747</url>
  </required_header>
  <id_info>
    <org_study_id>1585-CL-0011</org_study_id>
    <nct_id>NCT01124747</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug</brief_title>
  <official_title>An Open-Label Study to Evaluate the Disposition of 14C-Labeled ASP1585 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the systemic disposition of ASP1585 after oral&#xD;
      administration of 14C-labeled drug in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive study drug for 18 days with a radioactive dose of study drug given on&#xD;
      Day 15. Blood, urine and feces will be collected to confirm recovery of radioactivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excretion of radioactivity in urine</measure>
    <time_frame>Day 15 and up to Day 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Excretion of radioactivity in feces</measure>
    <time_frame>Day 15 and up to Day 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radioactivity assessment through analysis of blood samples</measure>
    <time_frame>Day 15 and up to Day 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP1585</condition>
  <arm_group>
    <arm_group_label>ASP1585 and 14C-Labeled ASP1585</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1585</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP1585 and 14C-Labeled ASP1585</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-Labeled ASP1585</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP1585 and 14C-Labeled ASP1585</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 and 32 kg/m2, inclusive and minimum body weight 45 kg&#xD;
&#xD;
          -  Agrees to sexual abstinence or to use a highly effective form of birth control which&#xD;
             includes a barrier method throughout the study&#xD;
&#xD;
          -  In good health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant disease&#xD;
&#xD;
          -  History of bowel obstruction, swallowing disorders, gastrointestinal disorders,&#xD;
             gastrointestinal surgery, actively bleeding hemorrhoids, or gastric/duodenal ulcers&#xD;
&#xD;
          -  Irregular bowel habits (&lt;1 bowel movement per day)&#xD;
&#xD;
          -  Clinically significant illness within 30 days&#xD;
&#xD;
          -  Received any drug or medicine (prescription or over-the-counter), including topical&#xD;
             medications, complementary and alternative medicines and vitamin and mineral&#xD;
             supplements within 14 days prior to the first dose of study drug&#xD;
&#xD;
          -  Received any investigational medication during the last 30 days or 5 half-lives,&#xD;
             whichever is longer, prior to screening&#xD;
&#xD;
          -  Consumes &gt;10 units of alcohol per week or history of alcoholism or drug/chemical abuse&#xD;
             within past 2 years&#xD;
&#xD;
          -  Smokes cigarettes or other nicotine-containing products&#xD;
&#xD;
          -  Anticipates an inability to abstain from alcohol use for 48 hours prior to first dose&#xD;
             of study drug or from grapefruit, Seville oranges, star fruit or products containing&#xD;
             these items from 72 hours prior to first dose of study drug until end of study&#xD;
&#xD;
          -  Positive drug or alcohol screen at Screening or Day -1&#xD;
&#xD;
          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma-glutamyl&#xD;
             transferase (GGT) value of &gt;2x upper limit of normal at Screening or Day -1&#xD;
&#xD;
          -  Known positive for human immunodeficiency virus (HIV), Hepatitis A, Hepatitis B or&#xD;
             Hepatitis C&#xD;
&#xD;
          -  Unwilling or unable to swallow large numbers of capsules&#xD;
&#xD;
          -  Significant blood loss, donated one unit of blood or more, or received a transfusion&#xD;
             of any blood or blood product within 60 days or donated plasma within 7 days prior to&#xD;
             Day -1&#xD;
&#xD;
          -  Known cumulative radiation exposure &gt;5 rems for the whole body, active blood forming&#xD;
             organs, ocular lens, and gonads, and &gt;15 rems for other organs&#xD;
&#xD;
          -  Has had nuclear medicine procedures, computed tomography scans, or significant x-rays&#xD;
             (other than dental) within the past 12 months, has received radiolabeled material&#xD;
             within the last 6 months, or has had significant occupational radiation exposure&#xD;
&#xD;
          -  Has participated in a radiolabled study within the last 6 months or participated in&#xD;
             more than one radiolabeled study within the last 12 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=1040</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 14, 2010</study_first_submitted>
  <study_first_submitted_qc>May 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <last_update_submitted>May 2, 2014</last_update_submitted>
  <last_update_submitted_qc>May 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP1585</keyword>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

